The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIconic Labs Regulatory News (ICON)

  • This share is currently suspended. It was suspended at a price of 5.375

Share Price Information for Iconic Labs (ICON)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.375
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 5.375
ICON Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Increase and Change to Management Agreements

7 Dec 2020 09:03

RNS Number : 7434H
Iconic Labs PLC
07 December 2020
 

 

 

 

Iconic Labs Plc ("Iconic Labs" or the "Company")

 

Increase in Management Services Fee to £125,000 a month and change to the Management Services Agreements

 

Iconic Labs Plc (LSE:ICON), a multidivisional new media and technology business, today announces that it has agreed with Greencastle Acquisition Limited ("Greencastle Capital") (which is the holding company of the JOE and HER Media and Lovin Media businesses) to change the basis on which the management services that are currently provided in respect of the JOE and HER and Lovin' Media businesses are provided going forwards.

 

The original management services contracts ("MSCs") were intended to be separate contracts and with a monthly fee of £100,000 for managing the JOE and HER Media businesses and a monthly fee of £10,000 for managing the Lovin' Media business. However, as these businesses are now being run together, Greencastle Capital has agreed to consolidate the management services that are currently being provided by the Company under separate MSCs into one combined single MSC for all of these management services. Consequently, the existing individual MSCs have been terminated and a new single combined MSC has been entered into. In addition, Greencastle Capital has agreed to increase the aggregate management fee to £125,000 per month, with all other terms remaining the same and, as part of the negotiations, and also to reflect the previously announced strategic partnership between Greencastle Capital and Premier Media Broadcasting Limited, the right to convert the £1 million term loan previously entered into between the Company and Greencastle MM LLP (of which Greencastle Capital is the 98% member) into equity in Greencastle MM LLP has been removed. Otherwise, the key provisions of the term loan remain the same which includes Greencastle MM LLP having the right to pre-pay the outstanding balance of the term loan in whole or in part at any time and otherwise the full amount of any outstanding amounts being payable at the end of its two year term, commencing from the date the loan was initially drawn down.

Market Abuse Regulation (MAR) Disclosure

The information contained within this announcement is deemed by the Company to constitute inside information for the purposes of the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

**ENDS**

For further information, please visit the Company's website www.iconiclabs.co.uk or contact:

Damon Heath

Shard Capital Partners LLP

Tel: +44 (0) 20 7186 9950

Iconic Labs ir@iconiclabs.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEANAXEEFEFEA
Date   Source Headline
1st May 20187:02 amRNSAnnual Accounts and Fundraising Update
26th Mar 20187:00 amRNSLandmark deal to launch CellPlan insurance in Asia
19th Mar 20187:00 amRNSGranted Innovate UK KTP for Stem Cell Research
27th Feb 20187:00 amRNSLicence Award from the Human Tissue Authority
19th Feb 20187:00 amRNSBoard Changes and Launch of Wideacademy Platform
21st Dec 20177:00 amRNSCorporate Update
2nd Nov 20177:00 amRNSRevenue generation with White Apex agreement
12th Oct 20177:00 amRNSCellPlan expansion, e-commerce platform launch UK
11th Oct 20177:00 amRNSPartner Secured to Expand into MENA & Asia-Pacific
29th Sep 20177:00 amRNSInterim Results
25th Sep 20177:00 amRNSWideacademy Update, Presenting at Investor Event
15th Aug 20177:00 amRNSRaises £750,000 to support Company's divisions
31st Jul 20177:00 amRNSResearch Licence Granted from HTA
24th Jul 20177:00 amRNSNew product to target the dental market
21st Jul 20177:00 amRNSCellPlan launches E-Commerce Platform in the UK
12th Jul 20177:00 amRNSCorporate Charity Commitment
4th Jul 20177:00 amRNSAgreement to Roll Out CellPlan in Brazil
3rd Jul 20177:00 amRNSInvestor Evening and CFO Now Employed Full-time
27th Jun 20177:00 amRNSRevenue with launch of CellPlan
22nd Jun 20173:30 pmRNSResults of AGM
22nd Jun 20177:00 amRNSAGM Statement and Notice of Investor Evening
12th Jun 20177:00 amRNSWideAcademy Strategic Update
6th Jun 20177:00 amRNSLaunch of CellPlan set to generate maiden revenues
2nd Jun 20177:00 amRNSWideCells Named 21st in Global DISRUPT 100 List
23rd May 20177:00 amRNSAttendance at British Dental Conference
15th May 20177:00 amRNSAttendance at Brazilian Conference
4th May 20172:15 pmRNSHolding(s) in Company
2nd May 20177:40 amRNSPosting of Report and Accounts and Notice of AGM
12th Apr 20171:00 pmRNSPlacing
30th Mar 20177:00 amRNSPreliminary Results
16th Feb 20177:00 amRNSBoard Appointment
31st Jan 20177:00 amRNSDirector Purchases and Grant of Options
30th Jan 20174:40 pmRNSSecond Price Monitoring Extn
30th Jan 20174:35 pmRNSPrice Monitoring Extension
26th Jan 201710:30 amRNSGrant of Options
24th Jan 20177:00 amRNSExtends CellPlan Roll Out & New Product Launch
9th Jan 20177:00 amRNSDefinitive Agreement with BioVault for CellPlan
30th Nov 20167:00 amRNSNew Revenue Stream: Stem Cell Research, Manchester
7th Nov 20167:00 amRNSLOI with 1st Cord Blood Bank to Roll Out CellPlan
24th Oct 20167:00 amRNSCorporate Update
10th Oct 20167:00 amRNSUpdate on CellPlan
27th Sep 20167:00 amRNSPartners with University of Westminster
5th Sep 20167:00 amRNSLaunches WideCells Brasil
12th Aug 20167:00 amRNSHoldings In Company
5th Aug 20167:00 amRNSUpdate on Manchester Facility and Appointments
27th Jul 20168:00 amRNSPlacing & First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.